ActiGraft is the first wound care product which enables health care providers to produce in vitro whole blood clots in real time for use as a chronic wound care product. Developed to address the need for cost effectiveness and clinical effectiveness of wound care.
• Simple to use
• Cost effective
ActiGraft system is intended to be used at point-of-care for the safe and rapid preparation of a whole blood clot from a small (10cc) sample of a patient's own peripheral blood. Under the supervision of a health care professional, the whole blood clot produced by the ActiGraft System is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.
Contraindicated for use on cancerous wounds, infected wounds, patients with active osteomyelitis, or deeply tunneling wound (more than 1.5cm deep).
Federal Law (U.S.A.) restricts this device to sale by or on the order of a physician. Throughout the processing and application of ActiGraft, use universal precautions as defined by the facility policy and procedure manual. All parts of the procedure shall be performed in such a manner as to minimize splashing, spattering, and generation of potential droplets.
Store at ambient temperature.
|Contact manufacturer for details|
|FDA cleared/approved for bone/tendon|
|FDA cleared/approved for burns||●|
|Kit components included||●|
|No centrifuge required||●|
|Portable preparation device||●|
|Same day procurement application||●|
|Educational Material Available||●|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
ActiGraft is applied weekly.
RedDress, a private medical device company, developed the proprietary patented technology for the first wound care product which enables health care providers to produce in vitro whole blood clots in real time for use as a chronic wound care product.